



IPGA TODAY

NEWSLETTER OF INDIAN PHARMACY GRADUATES' ASSOCIATION



Special Issue 2019

RNI No. : DELENG/2013/51512



Editorial Board

Editor in Chief

P. K. Jaggi

Editorial Board

Vijay Bhalla

Anil Kr. Negi

Dr. Kamla Pathak

Dr. Aarti R. Thakkar

Dr. Javed Ali

R. Mathangi

Advisory Board

Dr. G.N. Singh

Prof. B. Suresh

Prof. S. S. Agrawal

Prof. S. K. Kulkarni

S. W. Deshpande

S. L. Sobti

P. P. Sharma

S. L. Nasa

Prof. R. K. Khar

Prof. M.D. Burande

Prof. B.G. Shivananda

Ravi Uday Bhaskar

Shirish Dabade

Dr. Shahid Ansari

Dr. Satendra Rajput

'The IPGA TODAY'

is Official Newsletter

Published & Produced by

Indian Pharmacy Graduates' Association

F-2, A Block, DDA Shopping Complex,

Meera Bagh, New Delhi-110087

Inside :

From the Desk of President	01
Invited Article	02-07
Student Activities	08-10
Gazette Notification and Circulars	11-16
Scientific & New Drugs	17-18
Industry Updates	19
New Drugs	20
IPGA Annual Awards	21-32
33rd IPGA Report	33-36
Seminar Report	37-38
AIMST Report	39
IPC Report	40
IPGA New Members	41-43
IPGA WELFARE TRUST	44

From the Desk of President

Greetings!

The work of pharmacist is on display. It can be seen in the hospitals we visit many times and the families in which we live and work. Medicine these days are integral part of everybody's life. STEP fields (Science, Technology, Engineering and Pharmacy) produce innovators and problem solvers- professionals whose impact is far reaching and life changing. It was a team of pharmacists who created life benefitting pharmaceuticals.

IPGA is committed to educating the pharmacy professionals of tomorrow. Our members will be the individuals who will drive future innovations. But providing them a solid platform is only the beginning. We also must ignite within our members the passion to lead and to teach them to view mistakes as opportunities to improve. We also must instill in them the importance of guiding future generations to pursue innovations.

IPGA has been actively working by organizing informative seminars and conferences for the working pharmacists on the burning issues like prevention of microbial resistance, managing lifestyle diseases by active education, preventing medication errors, proper storage of medicines and digitalization of pharmacy services. Our emphasis is on getting suitable jobs to the passing out graduates by organizing mega job fests and pharma summits.

Our section of STUDENT FORUM is bubbling with energy to drive IPGA to newer heights with long list of activities like Internship fair, Leadership Talks, Career Counseling Fairs; Research Projects Ventures, Industrial Visits, and Community Based Programs. We wish the team a great success in their endeavor .We invite more and more pharmacy students to become a part of the next generation IPGAforefront.

We recently organized a well-attended 33rd Annual Conference of IPGA at Biswa Bangla Convention Centre at Kolkata.

Also an eight member strong team comprising of Executive members of Central Council of IPGA actively participated in AIMST International Conference 2019 at Bedong, Malaysia.

I am sure this issue of IPGA Today will provide you with the detailed information on the various professional activities of our association for the community and society we are living in.

Wishing all of you a very Happy New Year 2020.



Atul Kumar Nasa

Atul Kumar Nasa
President- IPGA

Managing Trustee- IPGA Welfare Trust
Vice President –AIDCOC

NEW AGE CAREER OPTIONS FOR PHARMACY GRADUATES AND POST-GRADUATES

Arti R Thakkar^{}, Vijay Bhalla[#]*

^{}Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, UP; [#]SGT College of Pharmacy, SGT University, Gurgaon, Haryana*

Indian pharmaceutical market is the third-largest in terms of volume and thirteenth-largest in terms of value. It is amongst the global leaders in providing quality generics to the world. India contributes the second largest share of pharmaceutical and biotech workforce in the world. Pharmaceutical sector in India was valued at US\$ 33 billion in 2017. India's pharmaceutical exports stood at US\$ 17.27 billion in 2018 and have reached US\$ 19.14 billion in 2019.

To have consistent growth of the pharmaceutical sector, traditionally pharmacy graduates and post-graduates follow the career path in various sections as mentioned in Figure 1.

However, the last decade has seen substantial accretion in industry valuations from adoption of biologics or biosimilars to artificial intelligence and data analysis. Several other important areas of innovation are likely to shape the future of the pharmaceutical sector; these include cell therapy, NGS-driven medications, and innovations in digital health. Along with these new age sciences or industrial revolution 4.0 pharmacy graduates role has been refined too.

Few new age career options for pharmacy graduates are as Market Research Analyst or Business Analyst and Data Analysts or Knowledge Management Executive. In both the roles basically one would be dealing with data only but as a Market Research Analyst or a Business Analyst one would be working with the perception of what kind of business strategies should be developed and what are the expectations of market and clients, as well the data collected by the



team would help to decide whether the strategies are in right directions or not. However, on the other hand, Data Analyst or Knowledge Management Executive deals with the research or data obtained after the clinical trials or other studies which needs to be coordinated or entered in the required software for further processing. Following is the detailed description and required skill sets for the business analysts.

Description of Job Role Business Analyst: Conduct primary and secondary research and collect data to prepare Competitive Intelligence, Business Intelligence Report (BIR) & Market Analysis of Pharmaceutical entity; Business Intelligence Report [Pharmaceutical Product trade data (Import and Export of API, FDF and intermediate), Market size estimation (Product annual sales and its %growth); New Molecule Research; Electronic Database searches; Database maintenance.

Required Skill Sets: Strong medical knowledge
Strong Commercial and market sense
Project management skills
Excellent communication skills
Conceptual, analytical & tactical thinking, strategic thought process
Ability to multi-task, work in a demanding global team environment, work under tight deadlines
Strong computer and MS Office skills.

INDIAN MEDICAL DEVICES REGULATIONS

Bharti Latwal¹, Rohit Bhatia¹, Arti R. Thakkar¹

Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida 201 313

Medical Devices are (i) substances used for in-vitro diagnosis and surgical dressings, surgical bandages, surgical staples, surgical sutures, ligatures, blood and blood component collection bag with or without anticoagulant covered under sub-clause (i);(ii) substances including mechanical contraceptives (condoms, intrauterine devices, tubal rings), disinfectants and insecticides notified under sub-clause (ii); and devices notified from time to time under sub-clause (iv), of clause (b) of section 3 of the Drugs and Cosmetics Act, 1940. In India, at present only notified medical devices are regulated as Drugs under the Drugs and Cosmetics Act 1940 and Rules made thereunder in 1945.

Whereas, USFDA defines a medical device as:"an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part or accessory which is recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them. Anything which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of

disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. While EU defines Medical devices as any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of: diagnosis, prevention, monitoring, treatment, or alleviation of disease diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap investigation, replacement or modification of the anatomy or of a physiological process control of conception and which does not achieve its principal intended action in or on the human body by pharmacological, immunological, or metabolic means, but which may be assisted in its function by such means.

Classification of Medical Devices according to Different Regulatory Agencies

Class	Risk Level	Device Examples
The Central Drugs Standard Control Organization (CDSCO), India		
A (Class I)	Low risk	Thermometers, Tongue Depressors
B (Class IIa)	Low-moderate risk	Hypodermic Needles
C (Class IIb)	Moderate-high risk	Lung Ventilators
D (Class III)	High risk	Heart Valves

United States Food and Drug Administration (USFDA), USA		
I	Low risk	Elastic Bandage, Gloves
II	Medium risk	Catheter, Needle
III	High risk	Pacemakers, Heart V

Class	Risk Level	Device Examples
European Medicines Agency (EMA), EU		
I	Low risk	Hospital beds
I	Low/Medium risk	Thermometer, weighing scales
IIa	Medium risk	Powered wheelchairs, hearing aids
IIb	Medium / High risk	Infusion pumps, ventilators
III	High risk	Implants, vascular and neurological replacement heart valves

The Pharmaceuticals and Medical Devices Agency (PMDA), Japan		
I	Extremely low	In-vitrodiagnostic devices
II	Low	MRI devices, Electronic Endoscope
III	Medium/High	Dialyzer, Bone Prosthetics
IV	Medium/High	Pacemaker, Artificial cardiac valve

Regulations of Medical Devices in India

The main concern of every country is the health of their public therefore stringent regulatory standards should be there to ensure the safety, quality and performance of any therapy used in treating the human and medical device is also not exception. The regulatory body of every country enhances the health of their public by providing safe and secure medicines; medical devices etc. and protect them from unwanted effects of the drugs, medical devices, biological products and any therapy.

Medical devices play an important role in health care system. They are the implements instruments, apparatus, equipments, software etc, which are helpful in the treatment, diagnosis, prevention and mitigation of disease and disorders. They can range from cotton to highly sophisticated pacemakers, stents etc. They are employed in all the branches of medicines, surgery and community all over the world. On the basis of their function, they have been classified as:

- (1) Preventive Care Devices;
- (2) Assistive Care Devices;
- (3) Diagnostic Devices and
- (4) Therapeutic Devices

CDSCO which is responsible for regulating the manufacturing, conduct of clinical trials, laying standards, import, sale, distribution and execution of Materiovigilance Programme of India (MvPI) of medical devices in India. This programme helps in collecting safety data so that decisions regarding safe use of medical devices can be made easily. Adverse events associated with medical devices are monitored with the help of this programme. Ten percent growth has been observed in the Indian market in last few years in healthcare industry and is anticipated to reach USD 280 billion by 2025. Medical devices sector in India is 4th largest in the Asia and it has many opportunities for both domestic as well as international manufactures. In 2017, Medical Device Rules 2017 have been established by CDSCO which came into effect on 1st January, 2018.

Medical Devices Rules, 2017


- These rules are published by Indian government to take over the Drug and Cosmetic Act, 1940.
- There was no particular law to regulate medical devices in India till January 2018.
- Rajya Sabha in 2006 rejected the medical device bill which was proposed to strengthen medical device sector.
- It has made the regulation of medical devices easier

by providing information about the regulatory requirements, quality management system and standards related to medical devices.

- Now it is easy to review, submit and track the registration document through SUGAM online system.

- Online electronic format for the submission of application to grant of permission is also available.

Approval Process for Online Application of Medical Devices



Responsibilities of Central Licensing Authority and State Licensing Authority

CENTRAL LICENSING AUTHORITY	STATE LICENSING AUTHORITY
Central licensing authority = DCGI imposes rules in matters related to:	State licensing authority = states drug controller which imposes rules in matters related to:
Import of medical devices of all class	Class A and class B medical device manufacturing for sale or distribution
Class C and class D medical devices manufacturing	Sale, stock, exhibit or offer for sale or distribution of medical devices of all classes
Evaluation of clinical performance and in-vitro diagnostics medical devices approval	
Regimentation with state licensing authority	

Notified Medical Devices

In India, following categories of medical devices are regulated as drugs under drug and cosmetic act, 1940 and rules 1945. These are the devices which are used either internally or externally in the treatment, diagnosis, prevention, mitigation or cure of disease or disorder in human beings or animals which are notified by government of India from time to time under drug and cosmetic act, 1940 and rules 1945.

CDSCO regulates the manufacturing, import, sale and distribution of these notified devices.

Now, many more devices are also going to be regulated as drugs in 2020. Notified medical devices:

Sr. No.	Name of the Devices	Date of Notification
1	Disposable Hypodermic Syringes	17.03.1989
2	Disposable Hypodermic Needles	17.03.1989
3	Disposable Perfusion Sets	17.03.1989
4	In-Vitro Diagnostic Devices for HIV, HBSAG & HCV	27.08.2002
5	Cardiac Stents	06.10.2005
6	Drug Eluting Stents	06.10.2005
7	Catheters	06.10.2005
8	Intra Ocular Lenses	06.10.2005
9	I.V. Cannulae	06.10.2005
10	Bone Cements	06.10.2005
11	Heart Valves	06.10.2005
12	Scalp Vein Set	06.10.2005
13	Orthopaedic Implants	06.10.2005
14	Internal Prosthetics Replacements	06.10.2005
15	Sutures and Ligatures	20.04.2010
16	Disinfectants	20.04.2010
17	Blood Grouping Sera	20.04.2010
18	Surgical Dressing	20.04.2010
19	Umbilical Tapes	20.04.2010
20	Condoms	20.04.2010
21	Intra Uterine Devices	20.04.2010
22	Vaginal Tubal Rings	20.04.2010
23	Ablation Devices	25.01.2016
24	Nebulizer	03.12.2018
25	Blood Pressure Monitoring Devices	03.12.2018
26	Digital Thermometer	03.12.2018
27	Glucometer	03.12.2018
28	All Implantable Medical Devices	15.05.2019
29	CT Scan Equipment	15.05.2019
30	Defibrillators	15.05.2019
31	Dialysis Machines	15.05.2019
32	PET Equipments	15.05.2019
33	MRI Equipments	15.05.2019
34	X ray Machine	15.05.2019
35	Bone Marrow Cell Separator	15.05.2019

Conclusion

Medical devices sector was largely unregulated in India until Medical Devices Rules in 2017. CDSCO is continuously working in making progress to make many devices which are not regulated under the regulations by issuing various notifications in time. More than ten devices have been notified recently under the category as “Drugs” as per the Drugs and Cosmetics Act 1940 and Rules 1945. Moreover, it is high time to strengthen the Materiovigilance Programme of India (MvPI) and more quality testing laboratories required to be established for quality assessment of Medical Devices in India for controlling the Medical Devices sector in order to prevent the outreach of faulty Medical Devices to the patients.

References:

1. Medical Devices and Diagnostics, Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Also Available from <https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/>
2. Division of Industry and Consumer Education, Center for Devices and Radiological Health, U. S. Food and Drug Administration (USFDA). Also Available from <https://www.fda.gov/medical-devices>
3. Regulation (EU) 2017/745 on Medical Devices (MDR) and Regulation (EU) 2017/746 on In-Vitro Diagnostic Devices (IVDR), European Medicines Agency (EMA), European Union (EU). Also Available from <https://www.ema.europa.eu/en/human-regulatory/overview/medical-devices>
4. Pharmaceuticals and Medical Devices Act (PMD Act), PMDA (Pharmaceuticals and Medical Devices Agency), Ministry of Health, Labour and Welfare, Japan. Also Available from <https://www.pmda.go.jp/english/review/services/regulatory-info/0001.html>

BEST FOODS FOR DIABETICS

1) CINNAMON : Research has suggested that cinnamon, in type-2 diabetes, helps to reduce blood glucose levels and increase insulin sensitivity. It improves insulin receptor function by activating enzymes that cause insulin to bind to cells (insulin receptor-kinase) and inhibits enzyme that blocks this process. 6 gms per day reduces LDL, Cholesterol and triglycerides. If 6 gms is taken for 40 days, can drop the blood glucose level by 25%. Best form is to brew cinnamon like tea and drink.

2) JAMMUN Total jammun fruit is very effective in diabetes. Seeds are rich in alkaloids which have hypoglycemic effect. They also increase insulin activity and sensitivity. 1 gm of powder taken three times a day can bring down the level of glucose by 30%.

3) ONION Contains high quantity of flavonoids (quercetin, cysteine, allyl propyl disulphide) which have the property to lower the sugar levels in diabetes. 50 gms of onion extract as juice controls the post prandial glucose levels.

4) FENUGREEK SEEDS It contains fibers and chemicals which slows digestion of carbohydrates and sugar. It also increases the insulin release. 4, hydroxyleucine- a novel amino acid present in seeds increases glucose simulated insulin release by isolated islet cells. In the morning drink 10 gms of seeds soaked in hot water over night.

5) ALO-VERA Alo-vera is packed with glucomannan which reduces glucose levels. The other components like anthraquinones, organic phenols and

lectins also regulate the sugar levels. Alo-vera cleans the body and eliminates excess glucose in the blood stream. It stimulates the secretion of insulin from the pancreatic beta cells. Alo-vera juice 50 ml taken twice a day regularly for two months brings a substantial change in sugar levels.

6) BROCCOLI Broccoli contains phytochemical Sulforaphane which can reverse the damage diabetes inflict on the blood vessels. It is recommended for diabetics because it contains antioxidant, minerals, vitamins and low calories. Broccoli also contains chromium which is required for GTF (glucose tolerance factor) thus helps to metabolize blood sugar. Broccoli should not be cooked but eaten in salads or stir fried.

Contd. on Page 16

WORLD PHARMACIST DAY CELEBRATION 2019:

World Pharmacist Day was celebrated on 28th September at **AMITY UNIVERSITY, Noida**. It invited about **450+** participants from more than **14 colleges** across Delhi-NCR. The theme of the day was **Safe and effective medicines for all**.

The day started with the conduction of Speakers' Forum to discuss the hot topics of the profession, EcoGreen (Best Out of Waste) competition to promote an eco-friendly yet an information generating activity, PharmaQuiz to check the general aptitude of students, Poster making competition to blend the theme-Safe and effective medicines for all into a sheet of creativity, Scientific Poster Presentation which invited a platform to present their research papers.

The fun element was something that took place parallel to all the indoor events i.e. Gully cricket and Tug of war. These fun events were incorporated to just bring about a refreshing change from the daily humdrums of life. The sportsmanship of each member participating in these fun activities was appreciate-worthy.

All the winners were provided with exciting cash prizes, gifts and certificates. The day ended with a valedictory ceremony which constituted the panel discussion on the theme of the day i.e **Safe and**

Effective medicines for all which was headed by *Ms Kriti Soni* (Head, Formulation Development, Dabur Research Foundation), *Prof. Dr Satyendra Rajput* (Amity Institute of Pharmacy), *Dr Nirupama Dhiman* (Amity Institute of Pharmacy). The evening was graced by the presence of pioneers of Pharmacy Profession - *Mr PK Jaggi* (Trustee, IPGA), *Mr Atul Nasa* (President, IPGA), *Dr Vijay Bhalla* (Treasurer, IPGA), *Dr Asim Ali Khan* (DG, AYUSH), and the senior teachers of Amity Institute of Pharmacy, Amity University, Noida. It continued with the felicitation of the previous year's council of IPGA-Student Forum (2018-2019) and the founding team of IPGA-Student Forum. As a part of every year's culture, Pharmacist oath was also taken. Badge ceremony for this year's council of IPGA-Student forum (2019-2020) was carried out followed by award ceremony for the winners. A special act of Nukkad Natak on the aforementioned theme by the theatre Society of DPSRU- Fitoor was enacted. An applaudable depiction of various Yoga Postures by Mr Suraj from Amity University was also witnessed. The day also contained with a mini celebration of Mr Atul Nasa's birthday. Our sponsors for the day were Wings Pharmaceuticals, Innova Captab Ltd, Unicare Pharmaceuticals, Pharmacognize and Dabur India Ltd.

GLIMPSES OF THE DAY:





IPGA SPONSORED INDUSTRIAL TOUR, 2019

About 120 students from seven pharmacy colleges across Delhi-NCR were shortlisted by the IPGA-SF council on the basis of online registration criteria who went to industries- **Tosc International, Supermax Drugs & Pharmaceuticals Private Limited, Ridley Life Science Pvt. Ltd. Dabur India Limited** on 9th September, 2019. Various IPGA-SF directors were allotted different industries where they led and coordinated their respective teams. It was a great

experience for the students to explore the working of the Pharmaceutical Industry. They were able to observe all that was read in the books live there including the various machines, chambers, chemicals etc. The overall mapping of the industry was shown to the students and importance of various chambers was also illustrated. It was a very exciting yet a great learning opportunity for the students.



रजिस्ट्री सं० डी० एल०-33004/99

REGD. NO. D. L.-33004/99



भारत का राजपत्र The Gazette of India

असाधारण

EXTRAORDINARY

भाग II—खण्ड 3—उप-खण्ड (i)

PART II—Section 3—Sub-section (i)

प्राधिकार से प्रकाशित

PUBLISHED BY AUTHORITY

सं. 378]

नई दिल्ली, सोमवार, जून 24, 2019/आषाढ़ 3, 1941

No. 378]

NEW DELHI, MONDAY, JUNE 24, 2019/ASADHA 3, 1941

स्वास्थ्य एवं परिवार कल्याण मंत्रालय

(स्वास्थ्य एवं परिवार कल्याण विभाग)

बधिसूचना

नई दिल्ली, 24 जून, 2019

सा.का.नि. 447(अ).—औषधि और प्रसाधन सामग्री नियम, 1945 का और संशोधन करने के लिए कतिपय नियमों के निम्नलिखित प्रारूप, जिसे केंद्रीय सरकार औषधि तकनीकी सलाहकार बोर्ड के परामर्श से औषधि और प्रसाधन सामग्री अधिनियम, 1940 (23 के 1940) की धारा 12 की उप-धारा (1) और धारा 33 की उप-धारा (1) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, इसके द्वारा प्रभावित होने की संभावना वाले सभी व्यक्तियों की जानकारी के लिए प्रकाशित किया जाता है और एतद् द्वारा सूचना दी जाती है कि उक्त प्रारूप नियमों पर उस तारीख से तीस दिनों की अवधि समाप्त होने पर या उसके बाद विचार किया जाएगा जिस तारीख को इन प्रारूप नियमों वाले भारत के राजपत्र की प्रतियां जनता को उपलब्ध कराई जाएंगी;

केंद्रीय सरकार द्वारा उपर्युक्त निर्दिष्ट अवधि के भीतर किसी भी व्यक्ति से प्राप्त होने वाली आपत्तियों और मुझावों पर विचार किया जाएगा;

आपत्तियां और मुझाव, यदि कोई हों, तो अवर सचिव (औषधि), स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार, कमरा सं. 414ए, डी विंग, निर्माण भवन, नई दिल्ली - 110011 को अग्रेषित किया जाए अथवा drugsdiv-mohfw@gov.in पर ई-मेल किया जाए

प्रारूप नियम

- (1) इन नियमों को औषधि और प्रसाधन सामग्री (.....संशोधन) नियम, 2019 कहा जाएगा
- (2) ये नियम आधिकारिक राजपत्र में इनके अंतिम प्रकाशन की तारीख को प्रभावी होंगे।

2. औषधि और प्रसाधन सामग्री नियम 1945 (जिसे इसमें इसके पश्चात् उक्त नियम कहा गया है) में, नियम 2 में,—

(i) खण्ड (ड) के पश्चात् निम्नलिखित खण्ड जोड़ा जाएगा, अर्थात्—

"(ड क) विपणनकर्ता का आशय उस व्यक्ति से है जो किसी अभिकर्ता के रूप में या किसी अन्य क्षमता में किसी दूसरे उत्पादनकर्ता द्वारा उत्पादित औषधि को विपणन की दृष्टि से उस औषधि पर लेबल करके या अपना नाम चस्पा करके उस औषधि के विक्रय और वितरण के लिए अंगीकृत करता है।"

(ii) खण्ड (ड क) के पश्चात् निम्नलिखित विद्यमान खण्ड (ड क) और (ड ख) को क्रमशः (ड ख) और (ड ग) क्रमांक माना जाएगा।

3. उक्त नियम में नियम 84घ के बाद निम्नलिखित नियम जोड़ा जाएगा, अर्थात्—

"84ड. औषधि विपणनकर्ता की जिम्मेदारी: ऐसा कोई भी विपणनकर्ता, जो किसी औषधि का विक्रय या वितरण करता है, इन नियमों के तहत औषधि की गुणवत्ता तथा अन्य विनियामक अनुपालनाओं के संबंध में उत्पादनकर्ता की भाँति जिम्मेदार होगा।"

4. उक्त नियम के नियम 96 में खण्ड (1) के उप-खण्ड (xii) के पश्चात् निम्नलिखित उप-खण्ड जोड़ा जाएगा, अर्थात्—

"(xiii) (क) किसी औषधि के विपणनकर्ता द्वारा औषधि के विपणन की स्थिति में विपणनकर्ता का नाम और पता:

बशर्ते कि यदि औषधि किसी संपुटक अथवा किसी छोटे शीशी में रखा है, तो केवल विपणनकर्ता का नाम प्रदर्शित किया जाना ही पर्याप्त होगा।"

[फा. सं. एक्स. 11014/22/2018-डीआर]

डॉ. मनदीप के. भण्डारी, संयुक्त सचिव

टिप्पण : मूल नियम अधिसूचना संख्या एफ. 28-10/45-एच (1), तारीख 21 दिसम्बर, 1945 द्वारा भारत के राजपत्र में प्रकाशित किए गए थे और अधिसूचना संख्या सा.का.नि.....(अ), तारीखद्वारा अंतिम बार संशोधित किए गए थे।

MINISTRY OF HEALTH AND FAMILY WELFARE

(Department of Health and Family Welfare)

NOTIFICATION

New Delhi, the 24th June, 2019

G.S.R. 447(E).—The following draft of certain rules further to amend the Drugs and Cosmetics Rules, 1945, which the Central Government proposes to make in exercise of the powers conferred by sub-section(1) of section 12 and sub-section(1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), in consultation with the Drugs Technical Advisory Board is hereby published for information of all persons likely to be affected thereby, and notice is hereby given that said draft rules will be taken into consideration on or after the expiry of a period of thirty days from the date on which copies of the Gazette of India containing these draft rules are made available to the public.

Objections and suggestions which may be received from any person within the period specified above will be considered by the Central Government.

Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 414A, D Wing, Nirman Bhavan, New Delhi - 110011 or emailed at drugsdiv-mohfw@gov.in.

DRAFT RULES

1. (1) These rules may be called the Drugs and Cosmetics (..... Amendment) Rules, 2019.
- (2) They shall come into force on the date of their final publication in the Official Gazette.

2. In the Drugs and Cosmetics Rules, 1945 (hereinafter to be referred as said rules) in rule 2,-
 - (i) after clause (e), the following clause shall be inserted, namely:—
“(ea) ‘Marketer’ means a person who as an agent or in any other capacity adopts any drug manufactured by another manufacturer for marketing of such drug by labeling or affixing his name on the label of the drug with a view for its sale and distribution.”
 - (ii) after clause (ea) the following existing clauses (ea) and (eb) shall be renumbered as (eb) and (ec), respectively.
3. In the said rules, after rule 84D, the following rule shall be inserted, namely:—
“84E. Responsibility of marketer of the drugs: Any marketer who sells or distributes any drug shall be responsible for quality of that drug as well as other regulatory compliances along with the manufacturer under these rules.”
4. In the said rules, in rule 96, after sub clause (xii) of clause (1), the following sub-clause shall be inserted, namely:—
 “(xiii) (a) the name of the marketer of the drug and its address, in case the drug is marketed by a marketer:
 Provided that if the drug is contained in an ampoule or a similar small container, it shall be enough if only the name of the marketer is shown.”

[F. No. X.11014/22/2018 -DR]

Dr. MANDEEP K. BHANDARI, Jt. Secy.

Note : The principal rules were published in the Official Gazette vide notification No. F. 28-10/45-H (1) dated 21st December 1945 and last amended vide notification number G.S.R.(E) dated.....

The Best Time to Take Walk for Diabetics

A surprising news that taking a walk before eating brings down the blood glucose levels. But whether we take a walk before or after food or both will bring down the sugar levels.

Taking a walk after dinner

is the best for diabetics but before dinner is still better.

Walk for 25 minutes, five days a week is recommended. Walking is also good for pre-diabetics in controlling sugar levels.

The researchers have found that intense physical

activity (fast walks) before meals help people with insulin resistance to control their blood glucose levels better than the standard recommendation to get one daily 30 minutes of moderate exercise.

PHARMACY COUNCIL OF INDIA

(Constituted under the Pharmacy Act, 1948)

E-MAIL : pcipresident@gmail.com
WEBSITE : www.pci.nic.in
Telephone : 011-61299900,
 011-61299901, 61299902
 011-61299903

NBCC Centre, 3rd Floor,
Plot No.2, Community Centre
Maa Anandamai Marg
Okhla Phase I
NEW DELHI – 110 020

Speed Post+Website

Ref.No.14-56/2019-PCI (Moratorium)
 (For online Application (Pt.I))

3720-3826

17 JUL 2019

To**All State Governments / Union Territories -**

1. Chief Secretaries 2. Principal Secretaries (Health) 3. Principal Secretaries
(Technical Education)

Subject: Moratorium for new D.Pharm and B.Pharm institutions from 2020-2021.

Sir/Madam

The Pharmacy Council of India (PCI) is a statutory body working under the Ministry of Health and Family Welfare, Government of India. It is constituted under the Pharmacy Act, 1948 to regulate the pharmacy education and practice of profession in the country by prescribing the minimum standard of education required for qualification for registration as a pharmacist.

At present, the following courses in pharmacy are being approved by the PCI u/s 12 of the Pharmacy Act, 1948.

Name of the Course	Duration of the course (Years)	Admission Qualification
Diploma in Pharmacy (D.Pharm)	2 yrs. & 500 hrs. practical training	- 10+2 science academic stream with Physics, Chemistry, Mathematics or Biology.
Bachelor of Pharmacy (B.Pharm)	4 yrs.	- 10+2 science academic stream with Physics, Chemistry, Mathematics or Biology. OR - Diploma in Pharmacy from PCI approved institution.

...2

.2.

Name of the Course	Duration of the course (Years)	Admission Qualification
Bachelor of Pharmacy (Practice)	2 yrs.	<ul style="list-style-type: none"> - D.Pharm from PCI approved institution. - Registered pharmacist with 4 yrs. Pharmacy Practice experience in community or hospital.
Doctor of Pharmacy (Pharm.D.)	6 yrs.	<ul style="list-style-type: none"> - 10+2 science academic stream with Physics, Chemistry, Mathematics or Biology. <p>OR</p> <ul style="list-style-type: none"> - Diploma in Pharmacy from PCI approved institution.
M.Pharm (Specialization)	2 yrs.	<ul style="list-style-type: none"> - B.Pharm

During the 106th Central Council meeting of the PCI held on 9th & 10th April, 2019, a concern was expressed about the mushrooming of pharmacy colleges in the country. The issue was threadbarely deliberated. It was noted that -

- There are approximately 1,985 D.Pharm and 1,439 B.Pharm institutes in the country. The annual intake of students in these institutes (both D.Pharm and B.Pharm) is 2,19,279.
- This available workforce is enough to meet the current pharmacist-to-population needs of the country.
- The rapid increase in the number of pharmacy colleges over the last decade may result in shortage of trained and qualified teaching faculty which may affect the quality of education imparted to students.
- The pass out students are not getting reasonably paid job opportunities in public as well as in private sector.

Considering the above facts, the House passed the following resolution unanimously:-

RESOLUTION


“Taking into consideration the availability of sufficient qualified pharmacist workforce, the House unanimously resolved to put a moratorium on the opening of new pharmacy colleges for running Diploma as well as Degree course in pharmacy for a period of five years beginning from the academic year 2020-2021. This moratorium shall not be applicable in the North Eastern region of the country where there is a shortage of pharmacy colleges.”

.3.

The said Resolution has been communicated to Ministry of Health and Family Welfare, Government of India on 17.7.2019 for information under intimation to All India Council for Technical Education (AICTE) and also posted on the Council's website.

This is for information and necessary action at your end.

Yours faithfully


(ARCHANA MUDGAL)
Registrar-cum-Secretary

BEST FOODS FOR DIABETICS

GARLIC The most important component of garlic is Allicin. This competes with insulin by inactivating sites in liver which results in no insulin inactivation. It also increases release of free insulin from beta cells. Garlic because of its antioxidant properties reduces the free radicals production and helps in diabetes. It also prevents from the damages to the organs due to diabetes by slowing down glycation process due to high sugar levels. Garlic can be taken with water or garlic oil soft gel capsules are available.

BASIL (TULSI) It is very potent

antioxidant therefore relieves oxidative stress, lowers triglycerides and LDL. It reduces blood fat and craving for sweets. Generates healthy beta cells for better production of insulin. Tulsi brings down fasting blood glucose levels. Basil taken in quantity of 200mg/kgm body weight for 30 days can lead to decrease of about 17% in sugar levels.

GREEN TEA Green tea contains polyphenols like EGCG (epigallocatechingallate) which helps to sensitize cells so they are better able to metabolize sugar. Obesity and diabetes are closely linked and green tea lowers body

fat thus helps in diabetes. The liver produces some glucose but the sugar spikes occur from the food we eat. Green tea reduces the amount of glucose that passes through intestines into the blood stream. Therefore green tea consumed with food will help to control the sugar levels in diabetes. When starch is consumed it requires enzyme amylase to break down into simple sugars and green tea inhibits the amylase and sugar is not converted. This controls sugar levels 3 to 4 sachets of green tea in a day will give the desired results.

SCIENTIFIC AND NEW DRUGS UPDATES

Bayer HealthCare Pharmaceuticals Inc. launches Nubequa (darolutamide) tablets

Nubequa (darolutamide), an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), is introduced by Bayer HealthCare Pharmaceuticals Inc. The drug got its approval on July 30, 2019 for the treatment of prostate cancer. The recommended dose of NUBEQA is 600 mg (two 300 mg film-coated tablets) taken orally, twice daily, equivalent to a total daily dose of 1200 mg. Swallow tablets whole with food. Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.

Thiola EC (tiopronin) by Retrophin, Inc.

Thiola EC (tiopronin) is a reducing and complexing thiol indicated for the prevention of cystine stone formation in patients with cystinuria, approved on June 28, 2019 under the company name of Retrophin, Inc. The recommended initial dosage of THIOLA in adult patients is 800 mg per day and in clinical studies the average dose of THIOLA was approximately 1,000 mg, or 10 pills per day. The original formulation of THIOLA 100 mg is recommended to be administered at least one hour before or two hours after meals. THIOLA EC 100 mg and 300 mg tablets are recommended to be administered with or without food. Pediatric patients receiving >50 mg/kg of tiopronin per day may be at increased risk for proteinuria.

Baxter International Inc. launched Myxredlin

Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. It was approved by FDA on June 20, 2019 under the brand name of Baxter International Inc. It contains 100 units/100 mL (1 unit/mL) of insulin human in 0.9% sodium chloride and is a clear, colorless solution available. Hypoglycemia is the most common adverse reaction of all insulins, including MYXREDLIN. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be

life threatening or cause death.

FDA establishes Nayzilam as a quality drug for seizure control

Nayzilam (midazolam), approved on May 17, 2019 by FDA, is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters. It is available in the market by the company name UCB, Inc. Administer NAYZILAM by the nasal route only. Do not use more than 2 doses of NAYZILAM to treat a seizure cluster. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe NAYZILAM concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation.

Ontruzant: by Samsung Bioepis Co., Ltd.

FDA approved Ontruzant (trastuzumab-dttb) on January 18, 2019. It is manufactured by Samsung Bioepis Co., Ltd. And is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Max daily dose Ontruzant 150 mg single-dose vial: 7 vials every 21 days. Max Units (per dose and over time). Breast Cancer and Gastric/Esophageal/Gastro-esophageal junction Cancers Load (billable units) Maintenance (billable units) 7-day dosing schedule 45 30 21-day dosing schedule 90 75 CNS Cancer. Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death. Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF).

FDA gives stamp to Gloperba

January 30, 2019 marked the approval of Gloperba (colchicine) by Romeg Therapeutics, LLC for gout. Gloperba (colchicine) is an oral solution formulation of the approved drug colchicine indicated for

SCIENTIFIC AND NEW DRUGS UPDATES

prophylaxis of gout flares in adults. For prophylaxis of gout flares, the recommended dosage of GLOPERBA is 0.6 mg (5 mL) once or twice daily. The maximum dose is 1.2 mg/day. GLOPERBA is administered orally, without regard to meals. Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.

Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules

Adhansia XR (methylphenidate hydrochloride) is an extended-release capsule formulation of the approved central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older. It was approved on February 27, 2019 and belongs to Adlon Therapeutics L.P. The recommended starting dose of ADHANSIA XR for patients 6 years or older is 25 mg once daily. Titrate the dose in increments of 10 to 15 mg at intervals of no less than 5 days. Dosages higher than 100 mg daily in adults and 85 mg daily in pediatric patients have not been evaluated in clinical trials and are not recommended.

Rocklatan (netarsudil and latanoprost) Ophthalmic Solution

Rocklatan (netarsudil and latanoprost ophthalmic solution) is a fixed dose combination of the Rho kinase inhibitor netarsudil (Rhopressa) and the prostaglandin F_{2α} analogue latanoprost (Xalatan), indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It got its approval on March 12, 2019 and is sold by Glaucoma (OpenAngle), Intraocular Hypertension. One drop in the affected eye(s) once daily in the evening. Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur.

Plenity (cellulose and citric acid) Capsules

Plenity by Gelesis (cellulose and citric acid) approved on April 12, 2019, is an oral, non-systemic, superabsorbent hydrogel used in conjunction with

diet and exercise to aid weight management in adults who are overweight or obese. It works by inducing a feeling of fullness so that patients eat less and lose weight. Each Plenity capsule contains thousands of superabsorbent hydrogel particles (0.75 grams [g] per capsule), and each particle is approximately the size of a grain of salt. Patients consume three (3) capsules (2.25 g/dose) with water before both lunch and dinner. Use with caution in patients with active gastrointestinal conditions such as gastro-esophageal reflux disease (GERD), ulcers, or heartburn. Avoid using in patients with the following conditions: Esophageal anatomic anomalies, including webs, diverticuli, and rings. Suspected strictures (such as patients with Crohn's disease). Plenity should be taken under the direction of an HCP as part of a structured weight loss program. Failure to adhere to prescribed dietary and exercise instructions may result in failure to lose weight.

FDA gives approval to Dengvaxia injection for prevention of dengue by Sanofi Pasteur

Dengvaxia got its approval on May 1, 2019 (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue caused by dengue virus serotypes 1, 2, 3 and 4 in people 9 years through 16 years of age living in endemic areas who have laboratory-confirmed previous dengue infection. It is manufactured by Sanofi Pasteur, Inc. The vaccination schedule consists of 3 injections of one reconstituted dose (0.5 mL) to be administered at 6-month intervals. DENG VAXIA administration to individuals not previously infected by dengue virus is associated with an increased risk of severe dengue disease when the vaccinated individual is subsequently infected with any dengue virus serotype. Therefore, healthcare professionals must evaluate individuals for prior dengue infection to avoid vaccinating individuals who have not been previously infected by dengue virus. There is no FDA cleared test available to determine a previous dengue infection. Available non-FDA cleared tests may yield false positive results (e.g., due to cross-reactivity with other flaviviruses).

PHARMACEUTICAL INDUSTRY UPDATES

- GSK completes \$95m investment for continuous manufacturing in Singapore: GSK opens two continuous manufacturing facilities and expands an existing production building to shorten timelines in the production of Daprodustat, a drug associated treatment of Anaemia with chronic kidney disease(6th August, 2019).
- Small molecule oncology drug market to exceed \$66bn in 2019: A recent study reported that sales of oncology small molecule drugs are forecasted to exceed \$66bn in 2019 up from \$63bn in 2018(12th July 2019).
- Warning Letter and Form 483 received by Indoco Remedies: Indoco Remedies confirms the receipt of a warning letter and form 483 for two different facilities based in Goa in a space of one week for oral dosage plant. The facility received four observations related to out-of-specifications batches and incomplete laboratory records(16th July 2019).
- Cipla announced that it has entered the Chinese market in a joint venture with Jiangsu Acebright. Cipla will set up a manufacturing plant for respiratory products in China under the joint venture. A combined total investment of \$30 million will be made for the joint venture. Cipla EU, a wholly-owned subsidiary of Cipla, will hold an 80% stake and Acebright will hold a 20% stake. Even though Cipla will start off with respiratory products in China, the pharma company aims to expand to other segments in the future(16th July 2019).
- Bengaluru-based firms Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG) and KemwellBiopharma have joined hands for global commercialisation of Stempeutics' stem cell product Stempeucel. Under the agreement announced on July 22, Kemwell will take a minority stake in Stempeutics and invest up to Rs 95 crore based on certain milestones as well as establish a world class cGMP cell therapy manufacturing facility at Kemwell's facility in Bengaluru for contract manufacturing of cell therapy products (24th July 2019).
- Pfizer and Mylan Combo: Pfizer creates “New Champion For Global Health” through the combining of its business unit and Mylan to establish a Pharmaceutical Company(29th July 2019).
- Sun Pharmaceuticals shuts down two R&D units in Vadodara: Sun Pharmaceutical Industries said it would be discontinuing operations at research and development centres in Vaodara - Tandalja and Akota. The company has also laid off some employees working at the two units. It, however, did not disclose the exact number. Market sources peg the number at 85 personnel who have been terminated and given three months salary in advance (2nd August 2019).

POTENTIAL DRUGS IN PIPELINE DRUGS LIKELY TO BE APPROVED BY FDA

1. Golodirsen (A gene therapy for Duchenne muscular dystrophy)

Duchenne Muscular Dystrophy (DMD) is a devastating and incurable muscle-wasting disease, associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. DMD is always fatal, usually before age 30, and generally due to respiratory or cardiac failure. If approved, Golodirsen will offer a new treatment option for DMD patients with a certain genetic makeup. While an existing medication in the class, Exondys-51™, works on the 13% of DMD patients.

2. Siponimod

Most people with the most common form of multiple sclerosis, relapsing-remitting MS (RRMS), go on to develop secondary progressive multiple sclerosis (SPMS) after 10 to 25 years since disease onset. SPMS is a form of MS that leads to progressive, irreversible disability, such as the need for enhanced walking aids and wheelchairs, bladder dysfunction and cognitive decline. Researchers have long sought a drug to delay onset of SPMS. Novartis Pharmaceuticals claims that siponimod is the first investigational medicine to show a significant delay in disability progression in typical SPMS patients. If approved, siponimod would be the first oral disease-modifying therapy for SPMS patients.

3. Zynquista™: An oral insulin adjunct for type 1 diabetes

Accordingly, patients with type 1 diabetes are dependent on injections of insulin to control blood sugar. Yet, studies show that most people with type 1 diabetes fail to meet glycemic guidelines. If approved, Zynquista™ (sotagliflozin) would be the first oral antidiabetic drug used in combination with insulin to control blood glucose levels in type 1 diabetics. Sotagliflozin has an FDA action date of March 22, 2019. Some analysts are optimistic about approval, citing strong efficacy and safety results presented at a European conference in early October.

4. Risankizumab

There is no shortage of drugs used to treat autoimmune conditions. Indeed, two drugs in this class, Humira and Enbrel, are currently first and second in overall spending for all medications in the U.S. Risankizumab is currently being evaluated by the FDA for the treatment of plaque psoriasis, an autoimmune disease. Risankizumab has demonstrated greater efficacy in reducing psoriasis symptoms in clinical trials vs. an existing market leader. Looking forward, risankizumab is also being studied for other autoimmune conditions, such as Crohn's disease and ulcerative colitis.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

LIFE TIME ACHIEVEMENT AWARD - 2019

on

**SHRI SHAM LAL NASA***in recognition of his outstanding contribution towards the Profession of Pharmacy*

during 33rd Annual Conference of IPGA at Kolkata, West Bengal

on Saturday, 17th August 2019

Shri Sham Lal Nasa, secured his D. Pharm. from Punjab University, Amritsar. He earned his B.Pharm and M. Pharm from College of Pharmacy (DIPSAR), Delhi University.

He started his career as a Hospital Pharmacist in Kalawati Saran Children Hospital (Lady Harding Hospital) and Safdarjang Hospital in 1956. He has more than 31 years of teaching experience at DIPSAR, New Delhi. He has actively contributed 60 years of his lifetime for the betterment of the Hospital Pharmacist and Pharmacy graduates.

He is one of the founder members of the IHPA (1963) & IPGA (1973). He was the Executive Secretary of All Indian Small Scale Manufacturers Association and editor of their Official Journal "AISSPMA" and Executive Director of Bulk Drug Manufacturers Association of Delhi Division.

He has many awards to his credits such as Best Pharmacist by Railway Pharmacists Association; M. L. Schroff Memorial National Award by IHPA; Best Teacher Award in Pharmacy by the Govt. of Delhi; Best Pharmacist Award by C.G.H.S. Pharmacists Association; Fellowship Award by Institute of Chemists; Fellowship Award by IPA; Life Time Achievement Award by IHPA; Best alumni award by DIPSAR, Delhi and Fellowship award by IPGA.

He has been holding various prestigious positions: Registrar, Delhi Pharmacy Council; Ex Ambassador of Indian Pharmacopoeia Commission; Director of Indian Confederation of Health Accreditation; President, IHPA; Ex Central Executive Member of IPCA from the last three decades; Advisor, IPGA; Central Executive member, IPA; Associate editor of Indian Journal of Hospital Pharmacy; Advisory board of Pharma Review & IPGA Today; Managing Trustee, Delhi Pharmacy Council Welfare Trust; Managing Trustee, Hospital Pharmacy Foundation and Trustee, IPGA Welfare Trust. He has delivered many invited lectures in national and international conferences.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**MR. SHIRISH K DABHADE***in recognition of his outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Mr. Shirish K Dabhadre is an alumnus of PCP, Pune University (B. Pharmacy) and Kakatiya University (M. Pharmacy).

He started his career as Management Trainee with Hindustan Antibiotics Limited, Pune and as a Trainee Manufacturing Chemist in Emcure Pharmaceuticals & German Remedies. Later he worked as a Lecturer Poona College of Pharmacy, Bhartiya Vidyapeeth, Pune. He was appointed as Drugs Inspector, State of Maharashtra in the Year 2011 and worked as Assistant Commissioner, FDA, Maharashtra.

He has served on various prestigious positions earlier: President – All India Drug Control Officers Confederation since February, 2011; Executive Council Member IPCA; Ex-Vice President – Indian Pharmacy Graduates Association; Ex-President – Drug Inspectors Welfare Association- Maharashtra State; Joint Secretary - 54th Indian Pharmaceutical Congress Trust Pune; Key Participation as LOC member for IPC since 2002; Ex-office bearer for IPA –Pune branch and IPA-Maharashtra State branch; Worked as Officer on Special Duty from January, 2008 – December 2008 with Hon. Minister of State for Food and Drug, Food & Civil Supplies, Labour – Maharashtra Government. He has received Best Drug Inspector award for Maharashtra from All India Drug Control Officers Confederation.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**MR. TAPAN K. CHAUDHARI***in recognition of his outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

MrTapan Kumar Chaudhuri, is a Pharmacy Graduate & Post Graduate from prestigious Jadavpur University (West Bengal) . He started his career as a Lecturer in West Bengal. He was appointed as Drug Inspector, Directorate of Drugs, West Bengal and promoted to Assistant Director of Drugs. He is an active member of IPGA and held many executive positions at the National Level as Joint Secretary-IPGA. He was also Associate Secretary to organize 70th Indian Pharmaceutical Congress 2018 at Amity University. He has organized many health awareness camps in West Bengal and held many career orientation programs and refresher courses for Pharmacists. In totality he has 25 year of rich experience in Regulatory and 6 years' experience in Academics. Presently he is Associate Professor, GNIPST, West Bengal

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**MR. RAJESH P. CHAUDHARI***in recognition of his outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Mr. Rajesh P. Chaudhari did B. Pharmacy from Pune University and MS in Pharmaceutical Technology & MBA from Bhartiya Vidyapeeth.

He started his career with Ranbaxy and also worked for Pure Health Pvt Ltd. & Khandalwal Laboratories Ltd. In 1993 he got selected as Drugs Inspector in FDA Maharashtra. Presently he is Assistant Commissioner, Pune. He is recipient of "Best Drug Inspector" award by ADICOC. He is recipient of the "FDA Person of Year" award at IPC Trust Pune. He participated in various training programs like Central Research Institute, Kasauli, H.P on manufacture of vaccines and sera; Homeopathic Pharmacopoeia Laboratory, Department of AYUSH (GOI) and Society of Nuclear Medicine (India) on Nuclear Energy for Better Health Care.

He is holding positions in many associations like Patron, Drugs Inspectors Welfare Association, Maharashtra State; Vice President (West Zone) of Indian Pharmacy Graduates' Association; Treasurer of Indian Pharmacy Graduates' Association (Maharashtra State Branch) and Joint Secretary of All India Drugs Control officers' Confederation.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**MS. SILKY SETHI***in recognition of her outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Ms Silky Sethy has done her B. Pharmacy and M. Pharmacy from GJU, Hissar, Haryana and pursuing Ph. D. from Amity University, Noida. Presently she is Associate Professor at K R Manglam University, Gurugram, Haryana. She is In charge of the Health Society of the University, Coordinator and In charge of Registration and Coordinator of the various Seminars, Workshops and Industrial Visits.

She has been Co-chairperson during 69th IPC, 65th IPC, 60th IPC. She has been poster evaluator and anchored many annual conferences of IPGA and valedictory session of IPC. She is an active Central Executive Council member of IPGA.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**DR. ARTI R. THAKKAR***in recognition of her outstanding contribution towards the Profession of Pharmacy*

during 33rd Annual Conference of IPGA at Kolkata, West Bengal

on Saturday, 17th August 2019

Dr. Arti R. Thakkar is alumnus of Pharmacy Department, M. S. University of Baroda, India. She was a visiting scholar at King's College of London, UK (during Ph. D.) and post-doctoral fellow at UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.

Dr. Thakkar has more than 14 years of National & International (India, UK, USA) experience in the Pharmaceuticals (DMPK, QA and DRA). She started her career as QC Chemist in Elysium Pharmaceuticals Ltd. She has worked as a faculty in Parul University, Baroda; ISF College of Pharmacy, Moga; Baddi University and Delhi Pharmaceutical Sciences and Research University, New Delhi. At present she is an Associate Professor at Amity University, Noida. In the past she has developed CDSCO approved commercialized drug testing laboratory ISF Analytical Laboratory (ISFAL), Moga.

Dr. Thakkar has 37 publications in peer reviewed journals; 66 Presentations in National and International (China, UK, USA) Conferences; 2 Indian Patents and 1 International Book Chapter, 6 Books (for B. Pharmacy and D. Pharmacy), 5 Research Projects (AICTE; INMAS; DST; NIH, USA and J&J, USA) worth Rs. 1 crore and 8 National & International awards to her credit. She has guided 34 M. Pharmacy Students and is presently guiding 2 Ph. D. Students. She is life member of IPGA, IHPA, APTI, SPER, MSU Pharmacy Alumni Association. She is member of AAPS and ISSX. She is active member in International Society of Study Xenobiotics (ISSX), Indian Chapter.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

FELLOWSHIP AWARD - 2019

on

**DR. NEERUPMA DHIMAN***in recognition of her outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Dr. Neerupma Dhiman is an Associate Professor, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida. In past, she has worked as faculty at Lord Shiva College of Pharmacy, Sirsa. She has more than 17 years of experience and her core research interests are Medicinal Chemistry, Natural Chemistry and Molecular Modeling specifically cancer and other non-communicable diseases.

Dr. Dhiman is alumnus of Panjab University, Chandigarh (B. Pharm. & M. Pharm.) and Dr. B.R. Ambedkar Biomedical Center, University of Delhi, Delhi (Ph.D.). She has published 15 research and review papers in peer reviewed journals and has published 2 book chapters and 2 books (B. Pharmacy) as well has 4 patents to her credit. She is Co-PI in one research project of AYUSH worth Rs. 12 lacs. She has guided seven M. Pharmacy and five Ph.D. students for their research work. She is reviewer of many scientific reputed journals. She is one of the senior faculty members of Amity Institute of Pharmacy and key contributor in developing system in the college. She is active member of IPGA Central Executive Council.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

PROFESSIONAL EXCELLENCE AWARD - 2019

on

**PROF. (DR.) SATYENDRA KUMAR RAJPUT***in recognition of his outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Prof. (Dr.) Satyendra Kumar Rajput has done his M.S. and Ph. D. in Pharmacology & Toxicology from NIPER, Mohali.

He has more than 13 years of experience in the small molecule drug discovery, herbal research, particularly involved in target identification and validation of novel therapeutic targets. In the past he has worked as faculty at ISF College of Pharmacy, Moga and Chitkara University, Chandigarh. Currently, he is professor, Amity Institute of Pharmacy and Director, Amity Institute of Indian System of Medicine, Amity University Uttar Pradesh, Noida. He is the initiator for Yoga related courses and Yoga workshops at Amity University.

Dr. Rajput has eight research projects worth Rs. 1 crore from DBT, AYUSH and Industry sponsored. He has eight patents and published more than 40 publications in peer reviewed journals. He has published 5 books and 7 book chapters. He has guided fifteen M. Pharm. and six Ph. D. students for their research work. He has received many national and international awards and has delivered invited talks in National and International conferences (Abu Dhabi, Dubai, France, USA). He has attended more than fifty workshops/conferences.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred

PROMISING PHARMACIST AWARD - 2019

on

**MR. KUSHAGRA BHALLA***in recognition of his outstanding contribution towards the Profession of Pharmacy*during 33rd Annual Conference of **IPGA** at Kolkata, West Bengal

on Saturday, 17th August 2019

Mr. Kushagra Bhalla has done his B. Pharmacy from Jamia Hamdard University, New Delhi in 2018 after his schooling from Amity International School, Delhi.

Presently he is working as Business Development Executive, Mankind Pharma., New Delhi. Before starting his career he has worked in many organizations as intern (NitiAyog, Health and Family Welfare Division), lead trainer for road safety (Uttar Pradesh Traffic Police), Associate (The Dais Foundation, New Delhi). He was Executive Director and Advisor to Kirat Youth Foundation for 2017-18 whose major mission was to create awareness about cleanliness, sanitation and personal hygiene.

He is Founding President of Indian Pharmacy Graduates' Association – Students Forum. He conceptualized the idea of IPGA Student Forum with the mission to promote the status of pharmacy profession and enhancement of public health through information, networking and professional initiatives. He was key contributor for constitutional affiliation and defining mandate, ideation of projects and events, outreach and social media publicity for IPGA-Students Forum.

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred



WEST BENGAL



WITH

**BEST STATE BRANCH
AWARD**

DURING
33rd IPGA ANNUAL CONFERENCE
WEST BENGAL
2019

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred



ALWAR



WITH

BEST LOCAL CHAPTER AWARD

DURING
33rd IPGA ANNUAL CONFERENCE
WEST BENGAL
2019

INDIAN PHARMACY GRADUATES' ASSOCIATION

Proudly Conferred



YAWALKAR ANKITA NITIN

RANK 1



MOHD RIYAZ BEG

RANK 2



VAIBHAV GHEGADE

JOINT RANK 3



ARCHANA KAPSE

JOINT RANK 3

WITH

**GPAT RANK HOLDERS
AWARD (2019)**

**DURING
33rd IPGA ANNUAL CONFERENCE
WEST BENGAL
2019**

**Report on 33rd Annual Conference of
INDIAN PHARMACY GRADUATES' ASSOCIATION (IPGA)
held on Saturday, August 17th 2019 at
Biswa Bangla Convention Centre, Kolkata, West Bengal
Theme: "Pharma Techies- Need Transformation"**

The 33rd Annual Conference of IPGA was organized by West Bengal State Branch at Kolkata, the city of joy. The Conference of IPGA was inaugurated on 17.08.2019 at state of the art, internationally designed, Biswa Bangla Convention Centre, Kolkata, West Bengal by Chief Guest **Shri B R Sikri**, Chairman, ABS Mercantile group of companies, a renowned entrepreneur and the Guest of honour **Shri Taranjit Singh** (Chief Patron), a promoter of Education & **Shri Atul Nasa**, President, IPGA & Controlling Authority, Drugs Control Department,

Govt of NCT Delhi, by Lighting the auspicious Lamp. The conference was aimed to meet the challenges in Pharmacy Education and the students trained with attributes that include critical thinking, communication skills, digital adaption & global understanding. The initial discussion of conference was to make future graduate Pharmacists with enhanced Pharmacy Practice Skills and knowledge. The conference was attended by more than 600 delegates from all parts of the country.



In their welcome address the Organizing Secretary of 33rd Annual Conference of IPGA **Shri Tapan Kumar Chaudhuri**, and President IPGA West Bengal State Branch, **Shri Goutum Sen** felicitated all the dignitaries on the dais and off the dais and gave detailed note about the conference.

Shri Atul Kumar Nasa, President IPGA in his address stressed upon the theme of the conference.

In his motivational words he requested students to come forward and take the lead by joining IPGA Student Forum, which is performing many professional nationwide activities under the banner of IPGA.

Dr Vijay Bhalla, Treasurer IPGA, Principal, SGT College of Pharmacy, SGT University, Gurugram, Haryana presented the detailed secretary report on

behalf of Dr. Arun Garg, General Secretary, IPGA, Professor & Dean, School of Medical & Allied Sciences, K R Mangalam University, Gurugram, Haryana. On behalf of IPGA, Dr. Vijay Bhalla announced the names of the recipient of various awards which were given away by the Chief Guest in the august presence of other dignitaries on the dais. Following life-members of IPGA were presented with prestigious awards by handing over a certificate, a citation and a memento by IPGA and another memento by IPGA Bengal State Branch:

In their welcome address the Organizing Secretary of 33rd Annual Conference of IPGA **Shri Tapan Kumar Chaudhuri**, and President IPGA West Bengal State

Branch, **Shri Goutum Sen** felicitated all the dignitaries on the dais and off the dais and gave detailed note on the conference.

Shri Atul Kumar Nasa, President IPGA in his address stressed upon the theme of the conference. In his motivational words he requested students to come forward and take the lead by joining IPGA Student Forum, which is performing many professional nationwide activities under the banner of IPGA.

Details of IPGA Awards given during 33rd IPGA ANNURAL CONFERENCE

IPGA Fellowship Awards	Mr. Tapan Kr. Chaudhuri,	ECM- West Bengal
	Mr. Rajesh P. Chaudhari,	ECM- Mumbai, Maharashtra
	Mr. Shirish K. Dabhade,	ECM- Pune, Maharashtra
	Dr. Arti R. Thakkar	ECM- 70th IPC (Amity University)
	Dr. Neerupma Dhiman	ECM- 70th IPC (Amity University)
	Ms Silky Sethy	ECM- 70TH IPC (Amity University)
IPGA Life Time Achievement	Shri Sham Lal Nasa	Registrar, Delhi Pharmacy Council
IPGA Professional Excellence	Prof (Dr.) Satyendra K. Rajput	Professor, Amity University
IPGA Promising Pharmacist	Mr. Kushagra Bhalla	Founder President , IPGA SF
IPGA BEST State Branch	West Bengal	Mr. Tapan & Mr. Goutam Sen
IPGA BEST Local Chapter	Alwar, Rajasthan	Dr. G Jeybalan
IPGA GPAT Rank Holders (2019)	Yawalkar Ankita Nitin (Rank-1)	Mumbai
	Mohd Riyaz Beg (Rank-2)	Mumbai
	Vaibhav Ghegade (Joint Rank-3)	Mumbai
	Archana Kapse (Joint Rank-3)	Mumbai

The Best Time to Take Walk for Diabetics

A surprising news that taking a walk before eating brings down the blood glucose levels. But whether we take a walk before or after food or both will bring down the sugar levels.

Taking a walk after dinner is the

best for diabetics but before dinner is still better.

Walk for 25 minutes, five days a week is recommended. Walking is also good for pre-diabetics in controlling sugar levels.

The researchers have found that

intense physical activity (fast walks) before meals help people with insulin resistance to control their blood glucose levels better than the standard recommendation to get one daily 30 minutes of moderate exercise.



Mr B R Sikri in his keynote address described the role of pharmacists in next decade, as pharma industry is growing at fast pace and requires skilled work force and technicians who are digitally competent, communicative and patient friendly. He compared Academicians as Brahma, Industrialists as Vishnu and youth force (students) as Mahesh as they are innovators and destroyers of the outdated ideas with novel techniques.

The vote of thanks was proposed by Mr Tapan Kumar Chaudhuri, Secretary, IPGA West Bengal State Branch. The inaugural session was followed by reciting National Anthem in honour of our country.

The scientific program comprised of the very useful lectures by:

1. Shri PP Sharma, Ex-Deputy Drug Controller, Delhi and Ex-Vice President, PCI, on the topic "**Pharmacy Practice-Opportunities and Challenges**"
2. Shri PK Jaggi, Ex-Licencing Authority, Delhi on the topic "**Safe disposal of Unused Medicines**"

3. Dr Ajmeer Ramkishan, Deputy Drug Controller, CDSCO, on the topic "**Blood transfusion-regulations**"

4. Mr Abhijit Ghosh, Assistant Drug Controller, CDSCO on the topic "**Medical Devices – Regulations**"

5. Poster presentation and evaluation by subject experts was carried out in a meticulous manner in a spacious and dedicated area. Over one hundred students from different Pharmacy colleges had participated in the Poster presentation.


6. Ms Prabhleen Pahwa and Ms R Mathangi presented the report on various activities conducted by IPGA Student Forum in the past one year and plan of action for the next calendar year. They motivated all the pharmacy students to join IPGA SF who were present to build a positive perception of profession of pharmacy in the eyes of the general public.



During the valedictory function, participation certificates were distributed to the delegates. This was followed by a memorable cultural evening which was filled with fantastic performance by a famous Bollywood singer.



At the end of the programme, Mr Tapan and Mr Goutam thanked the guests, speakers and the entire members of Local Organizing Committee (including management, faculty members, staff members and student volunteers) for making the event successful.



**Report on One Day Seminar of
INDIAN PHARMACY GRADUATES' ASSOCIATION (IPGA)
held on Saturday, 16th November 2019 at
University of Medical Sciences, Saifai, Etawah, Uttar Pradesh
Theme: "Recent Developments in Pharmaceutical Education"**

One day national Seminar on "Recent Developments in Pharmaceutical Education" was organized by Faculty of Pharmacy in the auditorium of Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh on 16th November 2019. In the inaugural session, Prof. Dr Devender Pathak presented the welcome address and briefed about the event. The dais was graced by Pro Vice Chancellor, UPUMS, Prof. (Dr) Ramakant Yadav, Registrar, UPUMS, Sh Suresh Chandra Sharan, Finance Controller, UPUMS, Sh. Gurjeet Kalsi, Medical Superintendent, UPUMS, Dr Adesh Kumar, Dr Atul



The deliberations of the seminar were spread across three scientific sessions wherein the speakers were introduced to the audience by Prof. Kamla Pathak, Faculty of Pharmacy, UPUMS, Saifai, Etawah. Scientific session-I had Dr Amita Tilak, Professor, Pharmacy Department, GSVM Medical College, Kanpur and Prof. (Dr) Vandana Arora, Group Director, Lloyd Group Of Institutions, Greater Noida as speakers. Dr Tilak elaborated the role Pharmacist as medication counselor and Dr Vandana deliberated management lessons to the audience on the topic



Nasa, President IPGA (Guest of Honor), along with the chief guest Prof. (Dr) Shailendra Saraf, Director, Internal Quality Assurance Cell, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh and currently officiating as President, Pharmacy Council of India. In his keynote address he focused on the paradigm shift in the pharmacy education emphasizing the importance of artificial intelligence, data mining, machine learning as contemporary learning tools. Accordingly introduction of new modules in the curriculum was emphasized by him.





“Leaders are made, not born”. The second scientific session consisted of talk on “Quality education in Pharmacy for ADR and Pharmacovigilance, by Dr Kashmira J Gohil, Director, Anand College of Pharmacy, Agra and Dr Atul Nasa, Dy Drug Controller, Drugs Control Department, Government of NCT of Delhi addressed the menace of Drug abuse and apprised the audience with the efforts of regulatory authorities in curbing it.

The third scientific session had three speakers. Mr PP Sharma, Ex-Deputy Drugs Controller, Delhi who elaborated on Antibiotic Resistance: the biggest threat to the mankind. He contemplated the issue and suggested some

measures to counter the threat. Mr P K Jaggi Ex-Asstt. Drugs Controller, Delhi delivered a very interesting and interactive talk on the manufacturing and regulatory control of Herbal Cosmetics. The guidelines presented by him were very useful for the budding pharmacists who dream to be entrepreneurs. Finally, Prof. (Dr) Vijay Bhalla, Principal, SGT College of Pharmacy, Gurugram, Haryana, addressed the audience and captivated them with his talk on Pharmacy as a profession: From a Chemist to Corporate.

The scientific sessions were followed by panel discussion wherein the professional queries by



the pharmacy students were addressed by an expert panel comprising of Dr Atul Nasa, Prof. (Dr) Devender Pathak, Prof. (Dr) Arun Garg, Mr. Bhanu Dua, Mr Anil Negi. The questions ranged from topics related to education, job opportunities and current regulatory updates. Finally the seminar was concluded with vote of thanks by Dr Praveen Kumar, Associate Professor, Faculty of Pharmacy, UPUMS, Saifai, Etawah. The event was a grand success with a total number of 600+ delegates from 24 colleges across Uttar Pradesh, Haryana and Delhi NCR.



The two days AIMST International Pharmacy Conference (AIPC) 2019 was held on November 30th 2019 and December 1st 2019 at AIMST University campus, Kedah, Malaysia.

It was attended by about 300 participants from different countries from all across the world. More than 40 delegates from India also attended. The event was jointly organized by Faculty of Pharmacy, Malaysian Pharmaceutical Society (MPS), Kedah/Perlis, Malaysia, and Indian Pharmacy Graduates' Association (IPGA), India.



The theme of the conference was 'Challenges and Opportunities in Pharmaceutical Sciences, Technology & Practice.'

The following topics were included in the scientific sessions during the Conference which were very informative and interesting:

- Precision Medicines
- Genomic Technology
- Clinical Pharmacy in precision Medicines
- Pharmacovigilance
- Plant based immunomodulators
- Contribution of social pharmacy in improving quality of life
- Collaborative drug discovery program
- Pharmaceutical Industries (Non-Manufacturing) - Career

More than 100 posters were presented for evaluation and 40 participants were enrolled and engaged in oral presentations.

A delegation comprising of Shri S L Nasa, Shri P P Sharma, Shri Pawan Kumar Jaggi, Mr Bhanu Dua, Shri S P Singh, Shri Tapan Kumar Chaudhuri, Dr Arun Garg and Dr Vijay Bhalla representing Indian Pharmacy Graduates' Association participated in the conference.

Shri S L Nasa representing IPGA had co-chaired the plenary and the inaugural session.

Shri Pawan Kumar Jaggi delivered a talk on the important topic **"Safe disposal of expired and unused medicines"** with the help of a power point presentation.

Dr Arun Garg Dean, School of Medical & Allied Sciences, KR Mangalam University, Gurugram

delivered a lecture on **"Life style disorders- how to prevent"** and

Dr Vijay Bhalla, Principal, SGT College of Pharmacy, SGT University, Gurugram, Haryana evaluated 36 posters as poster evaluator and also made a presentation on **Rational Use of Medicines**.



Congress was well organized by the Management, Faculty members and the students of the AIMST University and the delegates experienced the warmth of the Malaysian hospitality.



PARTICIPATION OF IPGA IN 71ST INDIAN PHARMACEUTICAL CONGRESS (IPC) AT CHENNAI - REPORT

A delegation of Indian Pharmacy Graduates' Association (IPGA) Executive Council members and Trustees of IPGA Welfare Trust participated in the 71st IPC at Chennai which was held at Chennai from December 20th 2019 to December 22nd 2019. The 71st Indian Pharmaceutical Congress (IPC)



successfully concluded on December 22, at the Sri Ramachandra Institute of Higher Education and Research (Deemed University) in Chennai with participation of pharmacy professionals from various sectors in the country. The three-day event was inaugurated by the motivational speaker and Additional Director General of Police (Railways), Dr. C. Sylendra Babu. Dr V G Somani, Drugs Controller General of India was Guest of Honour beside Presidents of all five federating Associations viz. AIDCOC, IPGA, IHPA, APTI and IPA. More than 8,000 delegates including students and teachers from various universities, working pharmacists from across Tamil Nadu and drugs control officers from southern states of the country attended the programme.



Shri Sham Lal Nasa, Registrar Delhi Pharmacy Council, President-IHPA and Trustee of IPGA Welfare Trust was conferred upon the prestigious K C Chatterjee Memorial Award during the inaugural session of 71st IPC. Shri S L Nasa also delivered the K C Chatterjee memorial lecture on first day on the topic



“Development of Hospital Pharmacy in India”. The president of IPGA and Managing Trustee of IPGA Welfare trust Mr Atul Nasa, DDC, Controlling cum Licensing Authority, Drugs Control Department, NCT Delhi was conferred upon prestigious M L Schroff memorial award during the inaugural session of 71st IPC. Dr Arul Garg, Secretary-IPGA participated as resource person in one of the scientific



session. The efforts of the Local Organizing Committee members of 71st IPC were appreciated for having organized such a mega event which was filled with scientific sessions, e- poster presentations, deliberations by eminent speakers and resource persons from India and abroad belonging to different fields of Pharmacy viz. Academia, Regulatory, Industry and Community Pharmacy.





























The Secretary-IPCA announced that the 72nd session of IPC will be hosted by Indian Hospital Pharmacists Association in the December 2020 and will be organized at Pharmaceutical Department at Nagpur University, Nagpur, Maharashtra. Dr V G Somani will preside over the 72nd session of IPC. Mr AK Nasa, Mr P P Sharma, Mr Bhanu Dua, Dr Vijay Bhalla, Mr Anil Kumar Negi, Mr Bharat Bhushan Mr Deepak Sharma, Dr Arti Ben Thakkar represented IPGA.

6701 Mr. Mahebbor Rahaman		6715 Mr. Pratham Bhatia		6729 Ms. Bhavya		6743 Ms. Vidya	
6702 Mr. Sukhendu Mondal		6716 Ms. Nancy		6730 Mr. Himanshu Sachdeva		6744 Mr. Ilhan Ahmed Khan	
6703 Mr. Partha Saha		6717 Mr. Sehajpreet Singh		6731 Ms. Alishah Raza		6745 Ms. Priya Tanwar	
6704 Mr. Gourav Sanajdar		6718 Mr. Piyush		6732 Mr. Aryan Sharma		6746 Ms. Priyanshi Sharma	
6705 Mr. Goutam Roy		6719 Ms. Himani Yadav		6733 Mr. Neeraj Kumar		6747 Mr. Laxit K Bhatt	
6706 Mr. Prokash Halder		6720 Ms. Bhawna Bansal		6734 Ms. Smitika Mitra		6748 Ms. Akanksha Singh	
6707 Mr. Santanu Prosad Dutta		6721 Ms. Bhavika		6735 Ms. Afifa Akram		6749 Ms. Simran Dixit	
6708 Mr. Sudip Kumar Ganguly		6722 Mr. Rahul Dagar		6736 Ms. Shreya Satija		6750 Ms. Apoorvi Suri	
6709 Mr. Rajiul Alam		6723 Ms. Sruthy Varghese		6737 Mr. Sarthak Yadav		6751 Ms. Jhalak Verma	
6710 Mr. Ratan Majumder		6724 Mrs. Anita Kurup		6738 Mr. Sanskar Gupta		6752 Ms. Shutkirti Bharti	
6711 Mr. Amit Kumar Ghosh		6725 Ms. Aleesha Mathew		6739 Mr. Tushar Dudeja		6753 Mr. Gaurav Kr. Burman	
6712 Mr. Koushik Maity		6726 Mr. Vaibhav Goel		6740 Mr. Avinash Prasad Verma		6754 Mr. Ravindra P. Gupta	
6713 Ms. Sayanika Ghosh		6727 Ms. Shivam Sharma		6741 Ms. Oshien Gole		6755 Mr. Puru Tuteja	
6714 Dr. Arti Singh Singh		6728 Ms. Tanya Agarwal		6742 Ms. Mansi Sharma		6756 Ms. Priyansha Bhatia	

Photographs of some of the new members couldn't be printed due to Non Availability of High Resolution Photograph. All such members are requested to forward soft copy of their photographs at pawankr52@gmail.com alongwith their Name and LM Number.

6757 Mr. Syed Ali H. Zaidi		6771 Mr. Ritesh Kumar		6785 Ms. Nidhi Verma		6799 Mr. Deepanshu Mishra	
6758 Mr. Raushan Kumar		6772 Ms. Jaya Singh		6786 Mr. Shailesh Kumar Singh		6800 Mr. Akshay Sachdeva	
6759 Mr. Dipesh Raj Singh		6773 Ms. Gunjan Kumari		6787 Mr. Sahaj Chhabra		6801 Mr. Yashasvi Vaid	
6760 Mr. Nikhil Kumar Pathak		6774 Ms. Km Sarika		6788 Mr. Dhruv Sharma		6802 Dr. Nagaraju Pappula	
6761 Mr. Subhash Chandra Giri		6775 Ms. Tanu Ranjan		6789 Ms. Jyoti		6803 Ms. Palak Jain	
6762 Mr. Amriendra Kumar		6776 Dr. Narendra K. Nyola		6790 Mr. Sandeep Chopra		6804 Ms. Kawal Jeet Kaur	
6763 Mr. Deepak Kumar		6777 Dr. Mujeebur Rahman		6791 Ms. Asra Jabeen		6805 Ms. Sreetama Moitra	
6764 Ms. Chandni		6778 Dr. Suresh Choudhary		6792 Mr. Abhinav Mittal		6806 Ms. Puspita Roy	
6765 Mr. Divyanshu Raj		6779 Dr. Shivli Nomani		6793 Mr. Naman Kumar Gupta		6807 Mr. Shovan Naskar	
6766 Mr. Manish Kumar		6780 Dr. Gazala Parveen		6794 Mr. Rajesh Kumar		6808 Mr. Sattik Mallick	
6767 Mr. Nitish Kumar		6781 Dr. Yogendra Singh		6795 Mr. Ramveer Singh Rana		6809 Mr. Soumyadip Ghosh	
6768 Mr. Ankit Kumar		6782 Dr. William A. Sundar		6796 Mr. Himansu Chopra		6810 Mr. Souvik Sarkar	
6769 Mr. Mukul Kumar		6783 Dr. Jeyaram B. Jeyabalan		6797 Mr. Sundeep K. Sharma		6811 Ms. Neha Biswas	
6770 Mr. Rajan Kumar Paswan		6784 Mr. Chandra K. Sharma		6798 Mr. Prabin Kumar Shahu		6812 Ms. Saptami Goswami	

Photographs of some of the new members couldn't be printed due to Non Availability of High Resolution Photograph. All such members are requested to forward soft copy of their photographs at pawankr52@gmail.com alongwith their Name and LM Number.

6813 Mr. Manu Singhai		6820 Mrs. Swrupa Arvapalli		6827 Ms. Navjit Kaur		6834 Dr. Parimalakrishnan	
6814 Ms. Ritu Saini		6821 Mrs. Shyamala		6828 Ms. Gurminder Kaur		6835 Mr. Anindya Banerjee	
6815 Mr. Anas Saifi		6822 Mr. Vikas P. Singh		6829 Ms. Ritu Saini		6836 Mr. Kasi S	
6816 Mr. Sachin Ashok Kamble		6823 Mr. Shiv K. Srivastava		6830 Ms. Chahanpreet Kaur		6837 Dr. Satish Shrishail Karoli	
6817 Mr. Vivek P. Khedkar		6824 Dr. Ajay Singh Kushwah		6831 Ms. Harpreet Kaur		6838 Dr. Limce Thampi	
6818 Mr. Aniket Upla		6825 Dr. Rahul Kumar Sharma		6832 Ms. Ramandeep Kaur		6839 Mr. Pardeep K. Suhag	
6819 Mr. Mukesh Bhardwaj		6826 Mr. Satvir Singh		6833 Mr. Tapan Kumar Mahto		6840 Dr. Gini E J	

* Due to Non Availability of High Resolution Photograph, we could not print it. Kindly forward soft copy of photographs at delhiexp45@hotmail.com alongwith your Name and LM Number.

PHARMACISTS' OATH

I promise to do all I can to protect and improve the physical and moral well-being of society, holding the health and safety of my community above other considerations. I shall uphold the laws and standards governing my profession avoiding all forms of misrepresentation and I shall safeguard the distribution of medical and potent substances.

Knowledge gained about patients I shall hold in confidence and never divulge unless compelled to do so by law.

I shall strive to perfect and enlarge my knowledge the better to contribute to the advancement of pharmacy and the public health.

I furthermore promise to maintain my honour and credit in all transactions and by my conduct never to bring discredit to myself or my profession nor to do anything to diminish the trust reposed in my professional brethren.

May I prosper and live long in favour as I keep and hold to this my oath but should I violate these sacred promises may the reverse be my lot.

I am a Pharmacist



Mission

To aid, assist & finance, establish and run, conduct conventions, scholarships, training, seminars, coaching, placements, consultancies, research projects, and such other activities as may be necessary for upliftment of members of Indian Pharmacy Graduates' Association and for the general public welfare particularly of women, children, senior citizens and handicapped persons of all castes and creeds.

RECENT SPONSORSHIPS BY IPGA WELFARE TRUST

		(Rupees)
09-09-2018	Scholarship to Nikita Sharma, MM COLLEGE OF PHARMACY, HARYANA	25000.00
30-06-2018	ALWAR COLLEGE OF PHARMACY, ALWAR	100000.00
17-07-2018	AMITY UNIVERSITY, NOIDA	25000.00
22-11-2018	ADITYA COLLEGE OF PHARMACY	50000.00
01-03-2019	KR MANGALAM UNIVERSITY, GURUGRAM	51000.00
17-07-2019	IPGA BENGAL BRANCH FOR 33 ANNUAL CONFERENCE OF IPGA	400000.00
26-06-2019	AMITY UNIVERSITY	25000.00
01-09-2019	IPGA BENGAL BRANCH FOR 33 ANNUAL CONFERENCE OF IPGA	100000.00
03-11-2019	IPGA UDAIPUR BRANCH FOR SEMINAR	70000.00

Trustees

Atul Kr. Nasa 9871318288 atulnasa@gmail.com 	S.L. Nasa 9313294423 slnasa@yahoo.co.in 	Bhanu Dua 9811072757 glycoremedies@yahoo.com 	P.K. Jaggi 9811168062 pk_jaggi@rediffmail.com 
S.L. Sobti 9811042169 slsobti@gmail.com 	P.P. Sharma 9871471515 mail.ppsharma@gmail.com 	Arun Garg 8470046553 agarg333@hotmail.com 	Anil Kr. Negi 9310053001 negikranil@gmail.com 
Bharat Bhushan 9810777569 bharat47_2005@yahoo.com 	Vijay Bhalla 9810540434 vijay_0434@hotmail.com 		

The IPGA Welfare Trust has decided to contribute a sum of Rs. 15000/- for IPGA Welfare Trust sponsored Conference/Seminar/Workshop* organised by an institute imparting degree course in pharmacy for the welfare of Pharmacy Graduates. (For sponsorship write to the managing trustee : atulnasa@gmail.com with detailed proposal)

Opinions expressed in IPGA TODAY are those of the authors and do not necessarily reflect the views of Indian Pharmacy Graduates' Association.

All rights reserved. Material from IPGA TODAY may be reproduced without written permission provided the source is acknowledged.

Regd. Off. : F-2, A-Block, DDA Shopping Complex, Meera Bagh, New Delhi-110087, India

Have you moved ?

If your correspondence address has changed, please forward your new address to IPGA-TODAY.

Edited and Published by : Mr. P.K. Jaggi, on behalf of the Indian Pharmacy Graduates' Association, F-2, A-Block, DDA Shopping Complex, Meera Bagh, New Delhi-110087, India